Latest news for Furukawa Battery (OTC:FRKWF) Stock

Furukawa Battery Co Ltd manufactures batteries for automobile, industrial infrastructure, disaster prevention and train, aircraft and space development industries. Automobile segment manufactures batteries for k-cars, mid-size cars, large size cars and motorcycles and also for hybrid and iss cars. Industrial infrastructure segment encompasses storage batteries combined with various power supply devices. Its products are the lead acid storage battery, alkaline storage battery, solar power generation systems for industrial use, battery condition watcher, automotive batteries, motorcycle battery, railway carrier batteries, cycle service storage batteries and power supplies. Automobile segment generates most of the revenues for the company.

FURUKAWA BATTERY CO by Furukawa Battery Co Ltd.

Furukawa Battery Co Ltd

Wells Fargo analyst Edward Kelly maintains Principal Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) with a Equal-Weight and lowers the price target from $87 to $85.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Principal Finl Gr, Lowers Price Target to $85

Earnings

CORRECTION: CNA Financial Q2 2024 GAAP EPS $1.19, Inline, Sales $3.52B Miss $3.55B Estimate

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Northwest Bancshares</h3>
<ul>
<li>The Trade: Northwest Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWBI#NASDAQ">NWBI</a>) CFO Douglas M Schosser <a href="https://www.benzinga.com/quote/NWBI/analyst-ratings">acquired a total of 7,000 shares</a> at  an average price of $14.19. To acquire these shares, it cost around $99,338.</li>
<li>What's Happening: On July 23, Northwest Bancshares posted upbeat quarterly results.</li>
<li>What Northwest Bancshares Does: Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and banking business solutions, investment management, trust services and insurance products.</li>
</ul>
<h3 class="wp-block-heading">Appian</h3>
<ul>
<li>The Trade: Appian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) 10% owner Colin T. Moran acquired a total of 120,200 shares at an average price of $35.95. To acquire these shares, it cost around $4.33 million.</li>
<li>What's Happening: On July 24, Keybanc analyst Thomas Blakey maintained Appian with an Overweight rating and raised the price target from $37 to $41.</li>
<li>What Appian Does: Appian is a low-code enterprise platform-as-a-service company focusing on business process management.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">Globe Life</h3>
<ul>
<li>The Trade: Globe Life Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) Director Mary E Thigpen <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 3,000 shares</a> at an average price of $90.20. To acquire these shares, it cost around $270,600.</li>
<li>What's Happening: On July 24, Globe Life posted better-than-expected quarterly earnings.</li>
<li>What Globe Life Does: Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984459/top-3-risk-off-stocks-that-are-set-to-fly-in-july">Top 3 Risk Off Stocks That Are Set To Fly In July</a></li>
</ul>

Long Ideas

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

APPN

NWBI

More Than $4M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying

Wedbush analyst Michael Pachter reiterates Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Outperform and maintains $33.5 price target.

Reiteration

Wedbush Reiterates Outperform on Unity Software, Maintains $33.5 Price Target

Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/avtr/earnings">earnings results on Friday</a>.
Avantor posted adjusted earnings of 25 cents per share, beating market estimates of 23 cents per share. The company posted sales of $1.703 billion, in-line with estimates, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
&#8220;Our teams delivered another solid quarter with sequential improvements to all key financial metrics. Improved mix from increased bioprocessing revenue together with the accelerated impact of our cost transformation initiative drove more than 100 basis points of sequential Adjusted EBITDA margin expansion, while disciplined working capital management led to free cash flow conversion above 100%,&#8221; said Michael Stubblefield, President and Chief Executive Officer. &#8220;We are reaffirming our fiscal year 2024 guidance and remain focused on executing our long-term growth strategy and delivering value to our customers and shareholders.&#8221;
Avantor shares gained 12.2% to close at $25.60 on Friday.
These analysts made changes to their price targets on Avantor following the announcement.
<ul>
<li>Baird analyst Catherine Schulte maintained Avantor with an Outperform rating, while raising the price target from $26 to $27.</li>
<li>Stifel analyst Daniel Arias maintained the stock with a Buy and raised the price target from $27 to $28.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40007912/top-4-energy-stocks-that-may-rocket-higher-in-q3">Top 4 Energy Stocks That May Rocket Higher In Q3</a></li>
</ul>

AVTR

Avantor Analysts Increase Their Forecasts After Better-Than-Expected Earnings

Wells Fargo analyst Elyse Greenspan maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Underweight and raises the price target from $287 to $300.

Wells Fargo Maintains Underweight on Aon, Raises Price Target to $300

Wedbush analyst Michael Pachter reiterates Cinemark Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) with a Outperform and maintains $25 price target.

Wedbush Reiterates Outperform on Cinemark Hldgs, Maintains $25 Price Target

Wells Fargo analyst Timur Braziler maintains First Interstate BancSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIBK#NASDAQ">FIBK</a>) with a Equal-Weight and raises the price target from $25 to $30.

FIBK

Wells Fargo Maintains Equal-Weight on First Interstate BancSys, Raises Price Target to $30

Global

BYDDF

TSLA

XPEV

China's BYD Lowers Prices By 50,000 Yuan On Hybrid SUV BAO 5 Under Offroad FANGCHENGBAO Lineup

Piper Sandler analyst Nathan Race maintains First Internet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBK#NASDAQ">INBK</a>) with a Neutral and raises the price target from $30 to $40.5.

INBK

Piper Sandler Maintains Neutral on First Internet, Raises Price Target to $40.5

WIIM

NAMS

NewAmsterdam Pharma shares are trading lower. The company announced its phase 3 BROOKLYN trial results for Obicetrapib in reducing LDL-C.

Wedbush analyst Nick McKay reiterates Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and maintains $46 price target.

RBLX

Wedbush Reiterates Outperform on Roblox, Maintains $46 Price Target

Oil Sales shares are trading higher after the company reported better-than-expected Q2 financial results.

Piper Sandler analyst Nathan Race maintains First Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRME#NASDAQ">FRME</a>) with a Overweight and raises the price target from $41 to $50.

FRME

Piper Sandler Maintains Overweight on First Merchants, Raises Price Target to $50

AAIC Poster Presentation Highlights XPro's&#x2122; Significant Effects on a Wide Range of Synaptic Proteins and Pathways
BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=Eq2O4sfQJqc5he9r4GnP2Yokfr2xxbsPCcZ1gBdJ33ioSAKSCHOBiGgLCQF3qc0-x5XpB9n84vmX42BWK-OuD2EIJXbacrDI5TA_7j7WM8bGpE228AvJK4VBghWisvzQyLt9VSiulyt4HEL8K9I2MjbiCKvtebUtZP6rsba_E4LiCTLcT1NPjlALlLPmrWW02Byl6Q19WYoKPtmwM2Th8_1xJ3Ez3IXbYBKaA7u01bFK3GeB2tanhFhVnqvq-Tj8">INmune Bio Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is pleased to be presenting results of a new and advanced proteomic analysis at this year's annual Alzheimer's Association International Conference (AAIC) in Philadelphia, PA. The poster summarizes dose-related changes in the cerebrospinal fluid (CSF) proteome in patients with Alzheimer's disease (AD) treated with XProTM in the company's phase 1b study.

Biotech

General

INMB

INmune Bio Presents New Phase 1 Study Data Demonstrating Dose-Dependent Effect Of XPro On Proteins That Regulation Synapses In Alzheimer's Patients In AAIC Poster Presentation

HTBK

Heritage Commerce shares are trading higher after the company reported better-than-expected Q2 revenue results. Also, multiple firms raised their respective price target on its stock.

CYTH

Cyclo Therapeutics Receives Grant Notice From European Patent Office For Patent On Methods For Treating Alzheimer's Disease; European Patent Number 3873604B To Be Published On August 21, 2024

Wells Fargo analyst Timur Braziler maintains First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) with a Underweight and raises the price target from $18 to $22.

Wells Fargo Maintains Underweight on First Hawaiian, Raises Price Target to $22

Wedbush analyst Daniel Ives reiterates Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Outperform and maintains $90 price target.

PEGA

Wedbush Reiterates Outperform on Pegasystems, Maintains $90 Price Target

Edible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>, EDBLW))), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that the Company's products are now available at Seasons Kosher and Lincoln Market retail locations.
Seasons Kosher, a local supermarket chain, is celebrated for its extensive range of kosher products, which are distinguished by a commitment to quality and ethical sourcing. Likewise, Lincoln Market, known for its fair pricing and diverse selection of high-quality, organic, and conventional products, will also begin carrying Edible Garden products.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Furukawa Battery

News

Latest news for Furukawa Battery (OTC:FRKWF) Stock